Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 19/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7387262 | 0.86 | GRM5 (0.51) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL6858302 | 0.79 | GRM5 (0.36) | GRM5 | |
| SCHEMBL14006347 | 0.78 | — | — | |
| SCHEMBL22610105 | 0.78 | GRM5 (0.35) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL4150082 | 0.78 | GRM5 (0.46) | GRM5 | |
| SCHEMBL28749297 | 0.77 | — | — | |
| SCHEMBL4145767 | 0.76 | GRM5 (0.72) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL18873238 | 0.73 | GRM5 (0.54) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL1434084 | 0.73 | GRM5 (0.63) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL29384255 | 0.73 | GRM5 (0.63) | GRM5CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111900477-A | High-voltage lithium ion battery electrolyte film-forming additive, electrolyte and battery thereof | 松山湖材料实验室 | 2020-11-06 | — | — | CN | claimed |
| US-RE49735-E1 | Oxazolidinones as modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-28 | — | — | US | disclosed |
| US-RE49735-E1 | Oxazolidinones as modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-28 | — | — | US | disclosed |
| US-RE49735-E1 | Oxazolidinones as modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827666-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2023-11-28 | — | — | US | disclosed |
| CN-114450282-A | Novel galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021004940-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2021-01-14 | — | — | WO | disclosed |
| CN-111900477-A | High-voltage lithium ion battery electrolyte film-forming additive, electrolyte and battery thereof | 松山湖材料实验室 | 2020-11-06 | — | — | CN | disclosed |
| US-10287220-B2 | Fluorination method | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-05-14 | — | — | US | disclosed |
| US-20180194767-A1 | 5-AROMATIC ALKYNYL SUBSTITUTED BENZAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-07-12 | — | — | US | disclosed |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
| EP-1556142-A4 | ALKYNE DERIVATIVES AS TRACERS FOR METABOTROPIC GLUTAMATE RECEPTOR BINDING | MERCK & CO INC (US) | 2006-11-08 | — | — | EP | disclosed |
| CN-1845915-A | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK & CO INC (US) | 2006-10-11 | — | — | CN | disclosed |
| EP-1664018-A1 | BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1556142-A2 | ALKYNE DERIVATIVES AS TRACERS FOR METABOTROPIC GLUTAMATE RECEPTOR BINDING | Merck & Co., Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005021529-A1 | BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004038374-A2 | ALKYNE DERIVATIVES AS TRACERS FOR METABOTROPIC GLUTAMATE RECEPTOR BINDING | MERCK & CO., INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004038374-A2 | ALKYNE DERIVATIVES AS TRACERS FOR METABOTROPIC GLUTAMATE RECEPTOR BINDING | MERCK & CO., INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-1214303-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Merck & Co., Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016121-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287220-B2 | Fluorination method | F13B, PPARG, PGC | GRM5 950/4885CYP1A2 316/4885CYP2D6 551/4885 |
| US-11827666-B2 | Galactoside inhibitor of galectins | LGALS1, LGALS2, LGALS3 | GRM5 1581/4885CYP1A2 2716/4885CYP2D6 3111/4885 |
| US-20180194767-A1 | 5-AROMATIC ALKYNYL SUBSTITUTED BENZAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | GRM5, GRIK5, GRM1 | GRM5 1/4885CYP1A2 1368/4885CYP2D6 990/4885 |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRM1 | GRM5 1/4885CYP1A2 1461/4885CYP2D6 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.